Capital Fund Management (CFM)
ENTA icon

Capital Fund Management (CFM)’s Enanta Pharmaceuticals ENTA Stock Holding History

Capital Fund Management (CFM)’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-12,175
Closed -$752K – 1675
2019
Q4 		$752K Buy
12,175
+4,175
+52% +$259K 0.01% 1227
2019
Q3 		$481K Buy
8,000
+1,800
+29% +$134K ﹤0.01% 1272
2019
Q2 		$523K Buy
+6,200
New +$558K ﹤0.01% 1206
2018
Q4 		– Sell
-4,100
Closed -$350K – 1944
2018
Q3 		$350K Buy
+4,100
New +$411K ﹤0.01% 1714
2015
Q1 		– Sell
-5,100
Closed -$259K – 1523
2014
Q4 		$259K Buy
+5,100
New +$228K ﹤0.01% 1402

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Capital Fund Management (CFM)'s ENTA Position: Q1 2020 in Review

Capital Fund Management (CFM) sold out of Enanta Pharmaceuticals (ENTA) in Q1 2020, closing a stake of 12,175 shares — an estimated $752K sold.

Capital Fund Management (CFM) first reported a position in ENTA in Q4 2014 and held it in 5 quarters. The position peaked at $752K in Q4 2019. 156 funds tracked by Wall St. Rank hold ENTA as of Q1 2020.

  • Capital Fund Management (CFM) reported no remaining Enanta Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 12,175 Enanta Pharmaceuticals shares in Q1 2020, an estimated $752K.
  • Capital Fund Management (CFM) first reported a position in Enanta Pharmaceuticals in Q4 2014 and held it in 5 quarters.
  • Capital Fund Management (CFM)'s Enanta Pharmaceuticals position peaked at $752K in Q4 2019.
  • 156 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2020.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2020, filed 13 May 2020.